

Publications on Coronary Artery Disease and Interventions Authored by MMI's Experts

Our diagnostic and interventional cardiologists have published extensively on coronary imaging and interventions, including atherectomy, angioplasty, stenting, and antiplatelet therapy. A sample bibliography is featured below citing publications over a 35-year period.

- Khalid U, Bando S, Jones PG, Virani SS, Hira R, Hamzeh I, Chan PS, Kleiman NS, Lakkis N, Alam M. **Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).** *American Journal of Cardiology* 2019; 124(12):1807-1812
- Khan MR, Kayani WT, Ahmad W, Manan M, Hira RS, Hamzeh I, Jneid H, Virani SS, Kleiman N, Lakkis N, Alam M. **Effect of Increasing Age on Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Older Adults with Unprotected Left Main Coronary Artery Disease: A Meta-Analysis and Meta-Regression.** *Clinical Cardiology* 2019; 42(11):1071-1078
- Kleiman N. **Guest Editor Neal Kleiman Leads Issue on the Current Status of Stents.** *Methodist DeBakey Cardiovasc j* 2018; 14(1)
- Kleiman N. **Stenting: the Latest Frontier in Percutaneous Intervention.** *Methodist DeBakey Cardiovasc j* 2018; 14(1):5-6
- Ibrahim H, Kleiman N. **Platelet Pathophysiology, Pharmacology, and Function in Coronary Artery Disease.** *Coronary Artery Disease* 2017
- Kleiman N, Kleiman NJ. **At Arm's Length: Radiation Safety During Radial Percutaneous Coronary Intervention.** *Journal of the American College of Cardiology* 2017; 69(20):2538-2541
- Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. **Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.** *JAMA Cardiology* 2017; 2(5):478-487
- Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman N, *et al.* **Bioresorbable Scaffold: The Emerging Reality and Future Directions.** *Circulation Research* 2017; 120(8):1341-1352
- Patel H, Kleiman NS. **Antiplatelet Therapy in Patients with Coronary Artery Disease.** In: *Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update.* *Springer International* 2017; 1361-1371
- Kalra A, Rehman H, Khera S, Thyagarajan B, Bhatt DL, Kleiman N, *et al.* **New-Generation Coronary Stents: Current Data and Future Directions.** *Current Atherosclerosis Reports* 2017; 19(3):14
- CHAMPION Investigators, **CHAMPION Investigators. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.** *Journal of the American College of Cardiology* 2017; 69(2):176-185
- Stolker JM, Cohen DJ, Kennedy KF, Pencina MJ, Arnold SV, Kleiman N, *et al.* **Combining Clinical and Angiographic Variables for Estimating Risk of Target Lesion Revascularization After Drug Eluting Stent Placement.** *Cardiovascular Revascularization Medicine* 2016
- Kleiman N. **VWF, ADAMTS13, and Acute Coronary Syndromes.** *Blood* 2016; 127(23):2788-2789
- Kleiman N. **What Happens in the Cath Lab Stays in the Cath Lab, or Does It? Intraprocedural Thrombotic Events in Patients with Acute Coronary Syndromes.** *JACC: Cardiovascular Interventions* 2016; 9(4):338-340
- IMPROVE-IT Investigators. **Ezetimibe Added to Statin Therapy After Acute Coronary Syndromes.** *New England Journal of Medicine* 2015; 372(25):2387-2397
- Kleiman N. **Is It Time to Join the Cult? Radial Access and Percutaneous Coronary Intervention.** *Circulation: Cardiovascular Interventions* 2015; 8(6). e002745
- Kleiman N. **Are We There Yet? Deciding When it is Safe (and Wise) to Stop Clopidogrel After Stent Implantation.** *Journal of Interventional Cardiology* 2014; 27(2):127-130

- Pershad A, Fraij G, Massaro JM, David SW, Kleiman NS, Denktas AE, *et al.* **Comparison of the use of Hemodynamic Support in Patients \geq 80 Years versus Patients $<$ 80 Years During High-Risk Percutaneous Coronary Interventions (from the Multicenter Protect II Randomized Study).** *American Journal of Cardiology* 2014; 114(5):657-664
- Cohen MG, Ghatak A, Kleiman NS, Naidu SS, Massaro JM, Kirtane AJ, Moses J, Magnus Ohman E, Džavík V, Palacios IF, Heldman AW, Popma JJ, O'Neill WW. **Optimizing Rotational Atherectomy in High-Risk Percutaneous Coronary Interventions: Insights from the PROTECT II Study.** *Catheterization and Cardiovascular Interventions* 2014; 83(7):1057-1064
- Dasari TW, Cohen DJ, Kleiman NS, Keyes MJ, Yen CH, *et al.* **Statin Therapy in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry).** *American Journal of Cardiology* 2014; 113(4):621-625
- VISTA-16 Investigators. **Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial.** *Journal of the American Medical Association* 2014; 311(3):252-262
- Chaikriangkrai K, Polsani V, Wei L, Kleiman N, Chang SM. **Stenting of a left main coronary artery compressed by a dilated main pulmonary artery.** *Catheterization and Cardiovascular Interventions* 2013
- Alam M, Virani SS, Shahzad SA, Siddiqui S, Siddiqui KH, Mumtaz SA, Kleiman NS, Coselli JS, Lakkis NM, Jneid H. **Comparison by meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting in patients with a mean age of \geq 70 years.** *American Journal of Cardiology* 2013; 112(5): 615-622
- Alam M, Huang HD, Shahzad SA, Kar B, Virani SS, Rogers PA, Paniagua D, Bozkurt B, Palacios I, Kleiman NS, Jneid H. **Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era - An aggregate data meta-analysis of 11,148 patients.** *Circulation Journal* 2013; 77(2):372-382
- Stolker JM, Cohen DJ, Kennedy KF, Pencina MJ, Lindsey JB, Mauri L, Cutlip DE, Kleiman NS. **Repeat revascularization after contemporary percutaneous coronary intervention: An evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.** *Circulation: Cardiovascular Interventions* 2012; 5:772-782
- Alviar CL, Tellez A, Wang M, Potts P, Smith D, Tsui M, Budzynski W, Raizner AE, Kleiman NS, Lev EI, Granada JF, Kaluza GL. **Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo.** *J Thromb Thrombolysis* 2012; 34(1):91-8
- Caputo RP, Goel A, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Waksman R, Tolerico P, Dhar G, Gordon P, Bach RG, Lopez JJ. **Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry).** *American Journal of Cardiology* 2012; 110(3):350-355
- Kleiman N. **Grabbing the Horns of a Dilemma: The Duration of Dual Antiplatelet Therapy after Stent Implantation.** *Circulation* 2012 ; 125(16):1967-1970
- Kleiman N. **Interventional Approaches to Acute Coronary Syndromes.** In: *Advances in Acute Coronary Syndrome Management. Future Medicine Ltd* 2012. p. 91-96
- Venkitachalam L, Lei Y, Magnuson EA, Chan PS, Stolker JM, Kennedy KF, *et al.* **Survival benefit with drug-eluting stents in observational studies: Fact or artifact?** *Circulation: Cardiovascular Quality and Outcomes* 2011; 4(6):587-594
- Stolker JM, Cohen DJ, Lindsey JB, Kennedy KF, Kleiman N, Marso SP. **Mode of Death After Contemporary Percutaneous Coronary intervention: A report from the Evaluation of Drug Eluting Stents and Ischemic Events registry.** *American Heart Journal* 2011; 162(5):914-921
- Lindsey JB, Kennedy KF, Stolker JM, Gilchrist IC, Mukherjee D, Marso SP, *et al.* **Prognostic implications of creatine kinase-mb elevation after percutaneous coronary intervention: Results from the evaluation of drug-eluting stents and ischemic events (EVENT) registry.** *Circulation: Cardiovascular Interventions* 2011; 4(5):474-480
- Venkitachalam L, Lei Y, Stolker JM, Mahoney EM, Amin AP, Lindsey JB, *et al.* **Clinical and economic outcomes of liberal versus selective drug-eluting stent use: Insights from temporal analysis of the multicenter evaluation of drug eluting stents and ischemic events (EVENT) Registry.** *Circulation* 2011; 124(9):1028-1037
- Giugliano RP, Pollack CV, Brogan GX, Cohen M, Diercks DB, Grines CL, *et al.* **Acute coronary syndromes: From the emergency department to the catheterization laboratory - Integrating evidence from recent ACS/NSTEMI trials into clinical practice: An evidence-based review of recent clinical trial results and report on a roundtable discussion.** *Journal of Interventional Cardiology* 2011; 24(2):119-136
- Mahaffey KW, Pieper KS, Likhnygina Y, Califf RM, Antman EM, Kleiman N, *et al.* **The impact of postrandomization crossover of therapy in acute coronary syndromes care.** *Circulation: Cardiovascular Quality and Outcomes* 2011; 4(2):211-219

- Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, *et al.* **Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.** *J Thromb Thrombolysis* 2011; 31(2):146-153
- Brilakis ES, Cohen DJ, Kleiman N, Pencina M, Nassif D, Saucedo J, *et al.* **Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: Results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.** *American Heart Journal* 2011; 161(2):360-366
- Brilakis ES, Cohen DJ, Kleiman N, Pencina M, Nassif D, Saucedo J, *et al.* **Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: Results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.** *American Heart Journal* 2011; 161(2):360-366
- Pollack CV, Brogan GX, Cohen M, Diercks D, Grines C, Henry TD, *et al.* **ED to catheterization laboratory: A roundtable integrating trials with practice.** *American Journal of Emergency Medicine* 2011; 29(9):1203-1216
- Berger PB, Kleiman N, Pencina MJ, Hsieh WH, Steinhubl SR, Jeremias A, *et al.* **Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement: Results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.** *JACC: Cardiovascular Interventions* 2010; 3(9):920-927
- Win HK, Kleiman NS. **Diagnosis and Treatment of Complications of Coronary and Valvular Interventions.** *Cardiac Intensive Care* 2010; 255-269
- Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, *et al.* **Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 evaluation of M118 in pErcutaNeous Coronary Intervention (EMINENCE) Trial.** *Circulation* 2010; 121(15): 1713-1721
- Stolker JM, Kennedy KF, Lindsey JB, Marso SP, Pencina MJ, Cutlip DE, *et al.* **Predicting restenosis of drug-eluting stents placed in real-world clinical practice derivation and validation of a risk model from the EVENT registry.** *Circulation: Cardiovascular Interventions* 2010; 3(4):327-334
- Kleiman N. **PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes.** *Current Cardiology Reports* 2010; 12(4):283-285
- French JK, Hellkamp AS, Armstrong PW, Cohen E, Kleiman NS, O'Connor CM, Holmes DR, Hochman JS, Granger CB, Mahaffey KW. **Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI).** *American Journal of Cardiology* 2010; 105(1):59-63
- Cohen M, Levine GN, Pieper KS, Lan L, Antman EM, Aylward PE, *et al.* **Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: A subgroup analysis from the SYNERGY trial.** *Catheterization and Cardiovascular Interventions* 2010; 75(6):928-935
- Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman N, *et al.* **Evaluation of a new heparin agent in percutaneous coronary intervention: Results of the Phase 2 evaluation of M118 in pErcutaNeous coronary intervention (EMINENCE) trial.** *Circulation* 2010; 121(15):1713-1721
- Granada JF, Alviar CL, Wallace-Bradley D, Osteen M, Dave B, Tellez A, *et al.* **Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent.** *J Thromb Thrombolysis* 2010; 29(1):60-69
- Lopez JJ, Keyes MJ, Nathan S, Piana R, Pencina M, Dhar G, Marso S, Rao S, Shammo S, Marquardt W, Cohen DJ and Kleiman NS. On behalf of the EVENT Registry Investigators. **Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era.** *American Heart Journal* 2010; 160(4):767-774
- Allocco DJ, Cannon LA, Britt A, Hell JE, Nersesov A, Wehrenberg S, Dawkins KD, Kereiakes and the TAXUS Investigators. **A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program.** *Trials* 2010; 11(1):1-15
- Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, *et al.* **Platelet inhibition with cangrelor in patients undergoing PCI.** *New England Journal of Medicine* 2009; 361(24):2318-2329
- Latif F, Kleiman N, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, *et al.* **In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents. A Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry.** *JACC: Cardiovascular Interventions* 2009; 2(1):37-45

- Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, *et al.* **In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents. Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry.** *JACC: Cardiovascular Interventions* 2009; 2(8):767-775
- Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, Rihal C, *et al.* **Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients. Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry.** *JACC: Cardiovascular Interventions* 2009; 2(11):1074-1082
- Holmes DR, Kereiakes DJ, Kleiman N, *et al.* **Combining Antiplatelet and Anticoagulant Therapies.** *JACC* 2009; 54(2):95-109
- Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ and GRAVITAS Trial Investigators. **Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial.** *Am Heart J* 2009; 157:818-24
- Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, *et al.* **Platelet inhibition with cangrelor in patients undergoing PCI.** *New England Journal of Medicine* 2009; 361(24):2318-2329
- Novack V, Tsyvine D, Cohen DJ, Pencina M, Dubin J, Dehghani H, *et al.* **Multivessel drug-eluting stenting and impact of diabetes mellitus - A report from the EVENT registry.** *Catheterization and Cardiovascular Interventions* 2009; 73(7):874-880
- Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, *et al.* **Prior polyvascular disease: Risk factor for adverse ischaemic outcomes in acute coronary syndromes.** *European Heart Journal* 2009; 30(10):1195-1202
- Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, *et al.* **Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease.** *Journal of the American College of Cardiology* 2008; 52(9):743-749
- Koshy SKG, Kleiman NS, George LK, Misra V, Hillegass WB, Brott BC. **Vascular changes and black hole phenomenon after coronary brachytherapy: A pathologically distinct entity.** *Journal of Invasive Cardiology* 2008; 20(10): 560-562
- Garg R, Tellez A, Alviar C, Granada J, Kleiman NS, Lev EI. **The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment.** *Catheterization and Cardiovascular Interventions* 2008; 72(2):205-209
- Kleiman N, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, *et al.* **Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.** *Platelets* 2008; 19(4):239-251
- Plana JC, Mikati IA, Dokainish H, Lakkis N, Abukhalil JM, Zoghbi WA. **A Randomized Cross-Over Study for Evaluation of the Effect of Image Optimization with Contrast on the Diagnostic Accuracy of Dobutamine Echocardiography in Coronary Artery Disease. The OPTIMIZE Trial.** *JACC Img* 2008; 1:145-52
- Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, *et al.* **Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.** *Circulation* 2008; 117(22):2865-2874
- Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, *et al.* **Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial.** *J General Internal Medicine* 2008; 23(3):310-316
- Raizner AE. **Magnetic navigation: a pivotal technology.** *Catheter Cardiovasc Interv* 2007;11
- Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB. **Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).** *Am J Cardiol* 2007; 99(8):1044-50
- Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, *et al.* **Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.** *Journal of the American Medical Association* 2007; 297(18):2001-9
- Hirohata A, Morino Y, Ako J, Sakurai R, Buchbinder M, Caputo RP, Karas SP, Mishkel GJ, Mooney MR, O'Shaughnessey CD, Raizner AE, *et al.* **Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial).** *Am J Cardiol* 2006; 98:1464-67
- Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, *et al.* **Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.** *American Heart Journal* 2006; 152(1):149-154
- Blankenship JC, Haldis T, Feit F, Hu T, Kleiman N, Topol EJ, *et al.* **Angiographic Adverse Events, Creatine Kinase-MB Elevation, and Ischemic End Points Complicating Percutaneous Coronary Intervention (a REPLACE-2 Substudy).** *American Journal of Cardiology* 2006; 97(11):1591-1596

- Lev EI, Tayyan N, Raizner AE, Solomon SL, Simmons D, Kleiman NS. **Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention.** *Coronary Artery Disease* 2006; 17(4):379-384
- Atmakuri SR, Lev EI, Alviar C, Ibarra E, Raizner AE, Solomon SL, *et al.* **Initial experience with a magnetic navigation system for percutaneous coronary intervention in complex coronary artery lesions.** *J Am Coll Cardiol* 2006; 47(3):515-521
- Mintz GS, Hong MK, Raizner AE, Lee CW, Kim JJ, Escolar E, Fearnot NE, Park SW, Park SJ, Weissman NJ. **Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents.** *Am J Cardiol* 2005; 95(1):105-7
- Rodriguez A, Granada J, Rodriguez-Alemparte M, Vigo CF, Fernandez-Pereira, Kaluza G, Raizner AE, Stone G (on behalf of ORAR II Investigators). **Long-term clinical and angiographic follow-up of oral rapamycin in patients undergoing coronary bare stent therapy: results of the randomized ORAR II trial.** *Eur Heart J* 2005; (26):694-5
- Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, Kleiman N. **Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era.** *American Heart Journal* 2005; 150(5):887-892
- Mintz GS, Hong MK, Raizner AE, Lee CW, Kim JJ, Escolar E, Fearnot NE, Park SW, Park SJ, Weissman NJ. **Intravascular ultrasound assessment of neointima distribution and length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.** *Am J Cardiol* 2005; 95:107-9
- Kaluza GL, Gershlick AH, Park S-J, De Scheerder I, Chevalier B, Camenzind E, Goy J-J, Missault L, Feifart N, Vrints C, Urban P, Shim WH, Ho DSW, Fearnot NE, Voorhees WD and Raizner AE. **Comparison of neointimal formation in polymer-free paclitaxel stents vs. stainless stents (From the ASPECT and ELUTES Randomized Clinical Trials).** *Am J Cardiol* 2004; 94:199-1
- Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ and Russell ME for the TAXUS-IV Investigators. **A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.** *N Engl J Med* 2004; 350(3):221-31
- Kaluza GL, Raizner AE. **Brachytherapy for restenosis after stenting for coronary artery disease: its role in the drug-eluting stent era.** *Curr Opin Cardiol* 2004; 19(6):601-7
- Jang IK, Lewis BE, Matthai WH, Kleiman N. **Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study.** *Journal of Thrombosis and Thrombolysis* 2004; 18(1):31-37
- Gershlick A, De Scheerder I, Chevalier B, Camenzind E, Vrints C, Reifart N, Missault L, Jean-Jacques G, Stephens-Lloyd A, Brinker J, Raizner AE, Urban P, Heldman A. **Inhibition of restenosis with a paclitaxel-eluting polymer-free coronary stent: The European evaluation of paclitaxel eluting stent (ELUTES) trial.** *Circulation* 2004; 109:487-93
- Kleiman N. **Platelets, the cardiologist, and coronary artery disease: Moving beyond aggregation.** *J Am Coll Cardiol* 2004; 43(11):1989-1991
- Labinaz M, Kaul P, Harrington RA, Chang WC, Kleiman N, Simoons ML, *et al.* **Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.** *Canadian J Cardiol* 2004; 20(8):773-778
- Granada JF, Kleiman N. **Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting.** *American Journal of Cardiovascular Drugs* 2004; 4(1):31-41
- Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE for the SIRIUS Investigators. **Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.** *N Engl J Med* 2003; 349-23
- Granada J, Kaluza GL, Raizner AE. **Drug-eluting stents for cardiovascular disorders.** *Curr Atherosclero Rep* 2003; 5(4):308-16
- Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, Stone G, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB. **Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial.** *Am J Cardiol* 2003; 91(9):1261-65
- Shirai K, Lansky AJ, Mintz GS, Costantini CO, Cristea E, Fahay M, Vandertie L, Yeung A, Raizner AE, Waksman R, Leon MB. **Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the intimal hyperplasia inhibition (INHIBIT) with beta in-stent trial.** *Am J Cardiol* 2003; 91(9):1113-5
- Choi D, Ho DS, Hong MK, Jang Y, Lam R, Lee CW, Mintz GS, Park SW, Park SJ, Raizner AE, Shim WH, Weissman NJ. **A paclitaxel-eluting stent for the prevention of coronary restenosis.** *N Engl J Med* 2003; 348:1537-45

- Mager DE, Mascelli MA, Kleiman NS, *et al.* **Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty.** *J Pharm Experim Thera* 2003; 307(3):969-976
- Grines C, Rubanyi GM, Kleiman NS, Marrott P, Watkins MW. **Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): A new option for the treatment of coronary artery disease.** *Am J Cardiol* 2003; 92(9 SUPPL 2):24-31
- Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, *et al.* **Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade during Percutaneous Coronary intervention: REPLACE-2 Randomized Trial.** *Journal of the American Medical Association* 2003; 289(7):853-863
- Waksman R, Raizner AE, Popma JJ. **Beta emitter systems and results from clinical trials. State of the art.** *Cardiovasc Radiat Med* 2003; 4(2):54-63
- Raizner AE, Kaluza GL. **The future of intravascular radiotherapy in the drug-eluting stent era. A personal perspective.** *Vasc Radioth Mon* 2002; 4:66-70
- Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, *et al.* **Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial.** *Circulation* 2002;105(7):788-793
- Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. **Use of localized intracoronary beta-radiation in treatment of in-stent restenosis: the INHIBIT randomized controlled trial.** *The Lancet* 2002; 59:551-7
- Fernandes, V, Kaluza GL, Godlewski B, Li G, Raizner AE. **Novel technique for stent delivery in tortuous coronary arteries: report of 3 cases.** *Catheter Cardiovasc Intervent* 2002; 55-485-490
- Kaluza GL, Zymek PT, Raizner AE. **Prevention of restenosis with intravascular beta-radiation for prevention of restenosis.** *Curr Atheroscler Rep* 2001; 3(2):169-173
- Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, *et al.* **Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.** *Circulation* 2001; 104(4):406-411
- Baim DS, Cutlip DE, O'Shaughnessy CD, Hermiller JB, Kereiakes DJ, Giambartolomei A, Katz S, Lansky AJ, Fitzpatrick M, Popma JJ, Ho KKL, Leon MB and Kuntz RE for the NIRVANA Investigators. **Final result of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries.** *Cardiol* 2001; 87(2):152-6
- Zymek PT, Kaluza GL, Raizner AE. **Intracoronary radiation for in-stent restenosis: what we have learned from clinical trials.** *Emondinamica* 2001; 26:2-7
- Raizner AE and Kaluza GL. **Coronary stenting or percutaneous transluminal coronary angioplasty prior to noncardiac surgery increases adverse perioperative cardiac events: the evidence is mounting.** *JACC* 2000; 36(7):2352
- Kaluza GL, Ali NM, Raizner AE. **Intracoronary radiotherapy for prevention of restenosis after percutaneous coronary interventions.** *Ann Med* 2000; 32(9):622-31
- Lansky AJ, Roubin GS, O'Shaughnessy CD, Moore PB, Dan LS, Raizner AE, Safian RD, Zidar JP, Kerr JL, Popma JJ, Mehran R, Kuntz RE, Leon MB. **Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses.** *Circulation* 2000; 102(12):1364-8
- Kaluza GL, Abukhalil JM, Raizner AE. **Nearly identical atherosclerotic lesions in left anterior coronary descending artery in identical twins.** *Circulation* 2000; 101(4): E63-4
- Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, *et al.* **Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial.** *Lancet* 1999; 354(9195):2019-2024
- Mazur W, Bitar JN, Lechin M, Grinstead WC, Khalil AA, Khan MM, Sekih S, Zoghbi WA, Raizner AE, Kleiman NS. **Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow.** *Am Heart J* 1998; 136(2):335-44
- Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, *et al.* **Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial.** *J Am Coll Cardiol* 1998; 31(1):31-36
- Levine G, Khan MM, Kleiman NS, Raizner AE, Jaroudi MO, *et al.* **Use of bare-mounted Palmaz-Schatz stents employing the stent saddle technique on the delivery balloon: a single center experience.** *Athet Cardiovasc Diagn* 1997; 41(4):361-8

- Mehta VY, Jorgensen MB, Raizner AE, Wolde-Tsadik G, Maher PR, Mansukhani P. **Spontaneous regression of restenosis: An angiographic study.** *J Am Coll Cardiol*1995; 26(3):696-702
- Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King SB, Raizner AE, Holmes DR, Kereiakes DJ, Topol EJ. **For the Gianturco-Roubin Intracoronary Stent Investigator Group. Major clinical events after coronary stenting: The multicenter registry of acute and elective gianturco-roubin stent placement.** *Circulation* 1994; 89(3):1126-37
- Mazur W, Ali NM, Raizner AE, French BA. **Coronary restenosis and gene therapy.** *Tex Heart Inst J*1994;21(1):104-11
- Lowry RW, Kleiman NS, Raizner AE, Young JB. **Is intravascular ultrasound better than quantitative coronary arteriography to assess cardiac allograft arteriopathy?** *Cathet Cardiovasc Diag*1994; 31(2):110-5
- Mazur W, Ali MN, Rodgers GP, Schulz DG, French BA, Raizner AE. **Directional atherectomy with the Omnicath®: A unique new catheter system.** *Cathet Cardiovasc Diag*1994; 31(1):79-84
- George BS, Voorhees WD III, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE, King SB, Holmes DR, Topol EJ, Kereiakes DJ, Hartzler GO. **Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes.** *JACC*1993; 22(1):135-43
- Zacca NM, Kleiman NS, Rodriguez AR, Heibig J, Warth D, Harris S, Minor ST, Raizner AE. **Rotational ablation of coronary artery lesions using single, large burrs.** *Cathet Cardiovasc Diag*1992; 26(2):92-7
- Zacca NMMD, Kleiman N, Asimacopoulos PJ. **High-speed coronary rotational angioplasty with the rotablator.** In: Abela GSMD, (Ed), Proceedings of SPIE - The International Society for Optical Engineering, Vol 1642. Int Soc for Optical Eng. 1992 p. 75-80
- Williams DO, Braunwald E, Knatterud G, Babb J, Bresnahan J, Greenberg MA, Raizner AE, Wasserman A, Robertson T, Ross R and TIMI Investigators. **One-year results of the thrombolysis in myocardial infarction (TIMI) phase II trial.** *Circulation* 1992; 85(2):533-42
- Kleiman NS, Rodriguez AR, Raizner AE. **Interobserver variability in the grading of coronary arterial narrowing using the american college of cardiology/american heart association grading criteria.** *Am J Cardiol*1992; 69(4):413-5
- Raizner AE, Minor ST, Siegel CO, Woolbert SC, Abukhalil JM, Roberts MA. **Dimensional stability of the Gianturco-Roubin balloon expandable stent assessed by quantitative coronary angiography.** *JACC*1991; 17(Suppl A):301A
- Harris SL, Staudacher RA, Heibig JP, Minor ST, Abukhalil JM, Kleiman NS, Raizner AE, Zacca NM. **Rotational coronary ablation achieves lumen size comparable to balloon angioplasty without stretching the arterial wall.** *JACC*1991; 17(Suppl A):124A
- Gray W, Bier J, Gewritz H. **Vasodilator Reserve Persists Distal to a Chronic Coronary Artery Stenosis Despite Reduced Myocardial Blood Flow.** *JACC*1991; 17(2)
- Rodriguez AR, Zacca N, Heibig J, Smith GS, Minor ST, Abukhalil JM, Raizner AE, Kleiman NS. **Coronary rotary ablation using a single large burr and without balloon assistance.** *Circulation*1990; 82 (Suppl III): III-310
- Kleiman NS, Raizner AE, Roberts R. **Percutaneous transluminal coronary angioplasty: Is what we see what we get?** *J Am Coll Cardiol*1990; 16(3):576-577
- Abukhalil JM. **Percutaneous Coronary High Speed Rotational Atherectomy: New, But How Safe?** *JACC*1990; 15:2
- Abukhalil JM. **Quantitative coronary cineangiogram analysis: a technical assessment.** *Radiol Technol*1990; 61(6):467-71
- Goldberg RK, Kleiman NS, Minor ST, Abukhalil J, Raizner AE. **Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA.** *Am Heart J*1990; 119(1):178-84
- Zacca NM, Raizner AE, Noon GP, Short HD III, Weilbaecher DG, *et al.* **Short term follow up of patients treated with a recently developed rotational atherectomy device and *in vivo* assessment of the particles generated.** *JACC*1988; 11:109A
- Zacca N, Raizner AE, Short D, Noon G, Weilbaecher D, Roehm J, Gotto Jr A, Roberts R. **First in-vivo human experience with a recently developed rotational atherectomy device.** *Circulation*1987; 76(Suppl IV):IV-46
- Passamani E and TIMI Investigators. **The thrombolysis in myocardial infarction (TIMI) Phase II Pilot: Tissue plasminogen activator (rt-PA) followed by percutaneous transluminal coronary angioplasty (PTCA).** *JACC*1987; 10:51B-64B
- Verani MS, Tadros S, Raizner AE, Phillips R, Matcek G, Lewis JM, Roberts R. **Quantitative analysis of thallium-201 uptake and washout before and after transluminal coronary angioplasty.** *Intl J Cardiol*1986; 13:109-124
- Jain A, Demer LL, Raizner AE, Roberts R. **Effect of inflation pressures on coronary angioplasty balloons.** *Am J Cardiol*1986; 57(1)